| 摘要 |
A use of (+)erythro-mofloquine substantially free of (-)erythro-mofloquine for the manufacture of a medicament for treating an inflammatory disease or an autoimmune disease such as rheumatoid athritis, osteoarthritis, psoriatic arthritis, psoriasis, Crohn's disease, systemic lupus erythematosus, ulcerative colitis, COPD or asthma is disclosed.
|
